Expiry of Drug Shelf Life During Prosecution Voids Analyst Report Finality: Jammu & Kashmir and Ladakh HC

The Jammu and Kashmir High Court has quashed a criminal prosecution under the drug control regime, ruling that the state's failure to facilitate a statutory re-analysis before the drug's shelf life expired constitutes a fatal violation of the accused's rights. The court held that once a manufacturer timely disputes a 'Not of Standard Quality' report, the document loses its conclusive evidentiary value, and the state cannot rely on it if the opportunity for independent laboratory testing is lost due to procedural delays.

In a judgment delivered by Justice Wasim Sadiq Nargal, the Court addressed a petition filed under Section 561-A of the Code of Criminal Procedure (equivalent to Section 528 of BNSS). The petitioners, a pharmaceutical company and its directors, challenged proceedings initiated under Section 18(a)(i) read with Section 27(d) of the Drugs and Cosmetics Act, 1940. The core of the dispute lay in the respondent's failure to send a disputed drug sample for re-analysis to the Central Drugs Laboratory (CDL) despite the petitioners expressing their intention to controvert the Government Analyst's report within the 28-day window provided by Section 25(3) of the Drugs and Cosmetics Act, 1940.

Key Takeaways

Displaced Conclusiveness

Once an accused notifies their intention to controvert a Government Analyst’s report within 28 days, the report’s status as 'conclusive evidence' is immediately denuded.

Mandatory Re-analysis Requirement

The word 'may' in Section 25(4) of the Drugs and Cosmetics Act, 1940 must be construed as 'shall' when its exercise is necessary to preserve the accused's statutory right to an independent laboratory opinion.

Shelf Life Sensitivity

If a drug's shelf life expires before the accused can move the Magistrate for re-analysis particularly due to delayed summons the prosecution becomes unsustainable as the statutory safeguard is rendered nugatory.

Substance over Form

A request for re-analysis by an 'NABL-accredited laboratory' rather than the 'Central Drugs Laboratory' does not constitute a waiver of statutory rights; the intention to dispute the report is the primary legal trigger.

The Mandatory Nature of Section 25(4)

The Court, in its reasoning, observed: "The expression 'may' occurring in Section 25(4) of the Drugs and Cosmetics Act, 1940 cannot be construed as conferring an unfettered discretion upon the learned Trial Court. ... Where the person has complied with Section 25(3) by notifying his intention to controvert the Government Analyst's report, and the statutory conditions for resorting to Section 25(4) are otherwise satisfied, refusal to facilitate examination of the sample by the Central Drugs Laboratory would deprive that person of the very statutory safeguard which the legislature intended to provide."

The bench placed heavy reliance on the Supreme Court's decision in Northern Mineral Ltd. v. Union of India & Anr. ( "(2010) 7 SCC 726": 2010 CaseBase(SC) 153), which established that a mere intention to adduce evidence in controversion implies a demand to send the sample to the central laboratory. The Court further noted that in the present case, the summons reached the petitioners in November 2016, a full year after the drug's expiry in November 2015, making meaningful re-analysis impossible.

Court Observations and Directions

The Court emphasized that the right to re-analysis is a valuable safeguard. Referring to M/s. Medicamen Biotech Ltd. and Another v. Rubina Bose, Drug Inspector ( "(2008) 7 SCC 196": 2008 CaseBase(SC) 2104) and State of Haryana v. Unique Farmaid (P.) Ltd. &Ors., the Court noted that the delay in filing the complaint or serving summons that leads to the expiry of the drug's shelf life prejudices the defence.

The Court has following directions:
"Accordingly, this Court finds that continuation of the impugned proceedings against the petitioners would cause manifest prejudice and would amount to permitting the prosecution to proceed without affording the petitioners the statutory safeguard available to them under the Act. The petition is, therefore, allowed. The impugned complaint titled State through Drug Inspector, Jammu v. Hussain Brothers and Ors., pending before the learned Chief Judicial Magistrate, Jammu, insofar as the present petitioners are concerned, the same is dismissed and all consequential proceedings arising therefrom, are hereby quashed."

Ratio

When an accused timely notifies the Inspector or the Court of their intention to controvert a Government Analyst’s report under Section 25(3) of the Drugs and Cosmetics Act, 1940, the report loses its conclusive character. The Court is then under a mandatory obligation to facilitate re-analysis by the Central Drugs Laboratory. If the shelf life of the drug expires due to delays not attributable to the accused before such re-analysis can occur, the accused is deprived of a vital statutory safeguard, rendering the continuation of the prosecution a futile exercise and an abuse of the process of law.

Background

On January 16, 2014, the Drug Inspector lifted samples of 'Amzone' (Batch No. MLI-386) from a hospital in Jammu. The Government Analyst declared the drug 'Not of Standard Quality' due to particulate matter. The petitioners, within 28 days of notice, expressed disagreement and requested re-analysis. Despite departmental internal notes to send the sample to the CDL, the respondent filed a complaint without making an application for re-analysis under the Drugs and Cosmetics Rules, 1945.

The petitioners argued they were deprived of their right under Section 25 of the Drugs and Cosmetics Act, 1940, citing Rakesh RanjanShrivastava v. State of Jharkhand ( "(2024) 4 SCC 419": 2024 CaseBase(SC) 416) and Hari Vishnu Kamath v. Syed Ahmad Ishaque. The state contended that the petitioners specifically asked for an 'NABL' laboratory, not the 'CDL', and thus waived their rights. Rejecting the state's argument, the High Court held that the legal fiction of 'conclusive evidence' in the analyst's report stands displaced the moment the intention to controvert is communicated, following the principles in State of U.P. and Others v. Babu Ram Upadhya and Municipal Corporation of Delhi v. Ghisa Ram ( "AIR 1967 SC 970": 1966 CaseBase(SC) 15).

Case Details:
Case No.: CRMC 17/2017
Case Title: Maxmed Life Sciences Pvt. ltd. and ors. v. State of Jammu and Kashmir
Appearances:
For the Petitioner(s): Mr. Varut Gupta, Advocate.
For the Respondent(s): Mr. Raman Sharma, AAG. With Ms. Salika Shiekh, AC

Source: 2026 CaseBase(JK) 1044